| INTRODUCTION
The BCL2-associated agonist of cell death (BAD) protein has a well-known role in cell apoptosis, but it also acts to regulate cellular metabolism. 1, 2 Genetic knockout of Bad (Bad KO) alters cellular metabolism, thereby reducing the ability of both neurons and astrocytes to utilize glucose, and increasing their ability to use ketone bodies (KBs) as fuel. 2 This cellular metabolic state is reminiscent of what occurs on the ketogenic diet (KD), a high fat, low carbohydrate diet used to treat pharmacoresistant epilepsy. 3 Despite the KD being used clinically for close to 100 years, its molecular mechanism is still incompletely understood. 4, 5 We previously found that, like mice on the KD, Bad À/À mice show resistance to acute chemoconvulsant seizures. 2 This effect was not due to the loss of BAD's apoptotic function; a mutation that maintains BAD's apoptotic role but prevents activation of glycolysis by BAD also provided seizure resistance in mice. This prompted us to examine whether Bad KO grants seizure protection in chronic epilepsy models, such as the Kcna1 À/À model of epilepsy in mice.
Loss-of-function mutations in the KCNA1 gene, which encodes for K v 1.1 channels, 6 can cause epilepsy in humans, 7 and targeted deletion of Kcna1 in mice results in neuronal hyperexcitability and spontaneous seizures. 6, 8 This developmental model of epilepsy causes progressively increased seizure severity that begins shortly after weaning and recapitulates the early death seen in sudden unexplained death in epilepsy (SUDEP). 
| Behavior monitoring
Male and female Kcna1 À/À (n = 29; 10 female, 19 male) and Kcna1 À/À Bad À/À (n = 15; 10 female, 5 male) mice were weaned on postnatal day 23 (P23). A 2-way analysis of variance (ANOVA) showed that variation in survival time was explained by genotype (P < .001) but not by sex (P = .6), and so data from male and female mice within genotype were pooled for comparison. Mice were singly housed in round Plexiglas cages (Pinnacle Technology Inc., Lawrence, KS, USA). Continuous recordings were obtained with ACTi (Model # D21) cameras using NVR3 software (ACTi Corporation Taipei, Taiwan); infrared illumination was automatically triggered at the onset of the dark phase to enable uninterrupted 24-hour recordings.
| Analysis
Seizures were scored and quantified by a trained experimenter blinded to genotype. Seizure behaviors were ranked on a modified Racine scale where a score of 0 indicated normal behavior. The seizure scores were assigned as fol Behavioral seizures were scored using a modified Racine scale (see Methods). Mice of both genotypes spent most of their time behaving normally and having stage 1 seizures (Figure 2A,B) . Both genotypes also spent considerable time exhibiting moderate (stage 2-3) seizures, and limited time in severe (stage 4-5) seizures (Figure 2A,B) . However, compared to Kcna1 
| DISCUSSION
This study shows for the first time that genetic knockout of Bad provides epileptic seizure protection in Kcna1
mice, a genetic model of epilepsy with SUDEP. Bad knockout provided seizure protection in both male and female mice. Based on previous work, 2 this effect is likely mediated by the nondietary effect of BAD on cellular metabolism, rather than its effect on apoptosis. We found that Kcna1 À/À Bad À/À mice had increased longevity and decreased spontaneous seizure severity, characterized by decreased time spent in seizures at P24 and the day of death. This is also the first time the Kcna1 gene has been deleted in the C57BL/6 mouse strain. We found that C57BL/6 Kcna1 À/À mice experienced frequent spontaneous seizures and hyperstartle responses, similar to those in previous studies performed in different mouse strains. 14 However, C57BL/6 Kcna1 À/À mice appear to have increased seizure severity and decreased lifespans, compared to values reported for Kcna1 À/À in other mouse strains. 6 We observed that nearly 80% of C57BL/6 Kcna1 À/À mice died by 5 weeks of age and that all died by 8 weeks of age. This is a higher mortality rate than previously reported in other Kcna1 À/À mouse strains. Smart et al, 6 reported that only 50% of Kcna1 À/À 129/Sv X N:NIHS-BC hybrid mice died between 3 and 5 weeks of age and that the rest survived to adulthood (while still experiencing spontaneous seizures).
The Kcna1 À/À model of epilepsy recapitulates the spontaneous seizures seen in patients with epilepsy 6 and early death that occurs in SUDEP. 9,10 KD and KB treatment decrease seizures and extend the lifespan of Kcna1 À/À mice. [10] [11] [12] [13] In addition, genetic deletion of Bad is associated with seizure resistance; when subjected to systemic chemoconvulsant injections of either kainic acid or pentylenetetrazol, Bad À/À mice had decreased seizure severity, compared to wild type mice. 2 This seizure resistance was not due to a lack of the apoptotic role of BAD because when BAD's ability to activate glycolysis was inhibited, but the apoptotic role of BAD was left intact, seizure protection ocurred. 2 We therefore wanted to test for seizure protection of Bad KO in a chronic seizure model. To do this, we tested seizures and lifespan in Kcna1 À/À and Kcna1 
